Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

/PRNewswire/ -- Acasti Pharma Inc. (Nasdaq: ACST and TSX-V: ACST) ("Acasti"; the "Company"), a late-stage specialty pharmaceutical company with drug delivery...

Related Keywords

United States ,Robert Blum ,Acasti Pharma ,Jan Dalvise ,Acasti Pharma Inc ,Partner Of Lytham Partners ,Lytham Partners ,Venture Exchange ,Nasdaq ,Lytham Partners Investor Conference ,Subarachnoid Hemorrhage ,New Drug Application ,Managing Partner ,Lytham Partners Summer ,Orphan Drug Designation ,Postherpetic Neuralgia ,